FDA approves Cabometyx for treating advanced neuroendocrine tumors in patients 12 and older.

The FDA has approved Cabometyx (cabozantinib) for treating patients aged 12 and older with previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors. This approval is based on a phase 3 trial showing improved progression-free survival and response rates compared to placebo. Common side effects include fatigue, hypertension, and diarrhea. The drug is now a standard treatment option for this patient group.